Business
Establishment Labs Surpasses Three Million Motiva Devices
Less than 1% device-related complication rates reported in post market surveillance data over 12+ years. NEW YORK--(BUSINESS WIRE)-- Establishment Labs
About this update from Establishment Labs Holdings Inc.
[{"type":"text","content":"\n\nLess than 1% device-related complication rates reported in post market surveillance data over 12+ years.\n\n\n NEW YORK--(BUSINESS WIRE)--\nEstablishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, announced that it has surpassed three million Motiva® devices in market.\n\n“Since its founding, Establishment Labs has been guided by one core principle: putting women at the center of everything we do,” said Juan José Chacón-Quirós, Establishment Labs CEO and Founder. “We let science, engineering, and evidence drive our research and development, and this is reflected in the outstanding performance of our portfolio of solutions for breast aesthetics and reconstruction. By leading with innovation for over twelve years now, we have transformed the future of this industry.”\n\n“The superior performance of Motiva is seen in our internal registries and warranty claims, as well as from independent registries and peer-reviewed publications, all of which are referenced in our annual Post Market Surveillance report,” said Dr. Heather Brennan, General Manager, Global Markets. “Our expectations for continued growth are clear: with our new Sulàyöm Campus, which is opening in July, we are more than doubling our manufacturing capacity to address the growing demand for Motiva. We believe that by setting new standards in safety and clinical performance, we will expand markets in breast aesthetics and reconstruction.”\n\nEstablishment Labs’ 2022 Post Market Surveillance Report is available at: Motiva PMS Report. Motiva Implants are undergoing an IDE clinical trial and are not approved for sale in the United States.\n\nAbout Establishment Labs\n\nEstablishment Labs Holdings Inc. is a global medical technology company dedicated to improving women’s health and wellness through the power of science, engineering, and technology. The Company offers a portfolio of Femtech solutions for breast health, breast aesthetics and breast reconstruction. The over three million Motiva® devices Establishment Labs has delivered to plastic and reconstructive surgeons since 2010 have created a new standard for safety and patient satisfaction in the over 85 countries in which they are available. The Motiva Flora® tissue expander is the onl...